{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:59:10Z","timestamp":1783573150170,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115204","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:00:36Z","timestamp":1752771636000},"page":"115204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance"],"prefix":"10.1016","volume":"163","author":[{"given":"Binglei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2025.115204_bb0005","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.juro.2012.06.020","article-title":"The clinical epidemiology of urachal carcinoma: results of a large, population based study","volume":"188","author":"Bruins","year":"2012","journal-title":"J. Urol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115204_bb0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","article-title":"Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases","volume":"34","author":"Szarvas","year":"2016","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115204_bb0015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/PAS.0b013e31819aa4ae","article-title":"Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation","volume":"33","author":"Gopalan","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115204_bb0020","doi-asserted-by":"crossref","first-page":"9106","DOI":"10.1002\/cam4.5648","article-title":"Preoperative accuracy of diagnostic evaluation of urachal carcinoma","volume":"12","author":"Ke","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00428-018-2467-1","article-title":"Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis","volume":"474","author":"Riva","year":"2019","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.intimp.2025.115204_bb0030","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cncr.22060","article-title":"Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy","volume":"107","author":"Ashley","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.juro.2007.03.022","article-title":"Urachal carcinoma: contemporary surgical outcomes","volume":"178","author":"Herr","year":"2007","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115204_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-5347(17)34950-9","article-title":"Urachal carcinoma: the case for extended partial cystectomy","volume":"151","author":"Herr","year":"1994","journal-title":"J. Urol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115204_bb0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","article-title":"Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases","volume":"34","author":"Szarvas","year":"2016","journal-title":"Urol. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115204_bb0050","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.21873\/anticanres.16775","article-title":"FOLFIRI chemotherapy for patients with metastatic urachal carcinoma","volume":"43","author":"Taniguchi","year":"2023","journal-title":"Anticancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2025.115204_bb0055","article-title":"Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma","volume":"30","author":"Zheng","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115204_bb0060","article-title":"Metastatic urachal carcinoma treated with several different combined regimens: a case report","volume":"16","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115204_bb0065","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.31547","article-title":"Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas","volume":"143","author":"Reis","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2025.115204_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drup.2005.03.002","article-title":"Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy","volume":"8","author":"Kelly","year":"2005","journal-title":"Drug Resist. Updat."},{"issue":"6","key":"10.1016\/j.intimp.2025.115204_bb0075","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.febslet.2006.01.087","article-title":"Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-pro(1)-cleaving specificity","volume":"580","author":"Edosada","year":"2006","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.intimp.2025.115204_bb0080","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in Cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0085","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-024-47068-z","article-title":"Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer","volume":"15","author":"Croizer","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2025.115204_bb0090","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","article-title":"Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic Cancer","volume":"12","author":"McAndrews","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.intimp.2025.115204_bb0095","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/gutjnl-2022-329371","article-title":"Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer","volume":"72","author":"Karamitopoulou","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0100","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2025.115204_bb0105","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.123.267248","article-title":"68Ga-fibroblast activation protein inhibitor PET\/CT improves detection of intermediate and low-grade sarcomas and identifies candidates for radiopharmaceutical therapy","volume":"65","author":"Lanzafame","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115204_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cpet.2023.02.008","article-title":"Fibroblast activation protein inhibitor Theranostics: the case for use in sarcoma","volume":"18","author":"Hamacher","year":"2023","journal-title":"PET Clin."},{"issue":"8","key":"10.1016\/j.intimp.2025.115204_bb0115","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2967\/jnumed.124.267473","article-title":"Fibroblast activation protein-directed imaging outperforms 18F-FDG PET\/CT in malignant mesothelioma: a prospective, single-Center","volume":"65","author":"Kessler","year":"2024","journal-title":"Observ. Trial. J Nucl Med."},{"issue":"11","key":"10.1016\/j.intimp.2025.115204_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"12","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115204_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.intimp.2025.115204_bb0130","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.intimp.2025.115204_bb0135","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115204_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/biom13010062","article-title":"The Cancer-associated fibroblasts-related gene COMP is a novel predictor for prognosis and immunotherapy efficacy and is correlated with M2 macrophage infiltration in Colon Cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115204_bb0155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.intimp.2025.115204_bb0160","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of Cancer-associated fibroblasts promote T-cell exclusion in human lung Tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.intimp.2025.115204_bb0165","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting Cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.intimp.2025.115204_bb0170","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2025.115204_bb0180","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.trecan.2023.06.002","article-title":"Collagen architecture and signaling orchestrate cancer development","volume":"9","author":"Su","year":"2023","journal-title":"Trends Can."},{"issue":"7","key":"10.1016\/j.intimp.2025.115204_bb0185","first-page":"1045","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat. Can."},{"issue":"2","key":"10.1016\/j.intimp.2025.115204_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00784-007-0165-5","article-title":"Natural killer cells and alterations in collagen density: signs of periradicular herpesvirus infection?","volume":"12","author":"Saboia-Dantas","year":"2008","journal-title":"Clin. Oral Investig."},{"issue":"6","key":"10.1016\/j.intimp.2025.115204_bb0195","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41422-023-00810-6","article-title":"SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches","volume":"33","author":"Wu","year":"2023","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0200","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1038\/s41467-022-32255-7","article-title":"Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis","volume":"13","author":"Papanicolaou","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2025.115204_bb0205","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155148","article-title":"Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-\u03b2 signaling enables PD-L1-mediated tumor eradication","volume":"132","author":"Horn","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12943-023-01876-x","article-title":"Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment","volume":"22","author":"Ma","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115204_bb0220","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","article-title":"Cancer-associated fibroblast classification in single-cell and spatial proteomics data","volume":"14","author":"Cords","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2025.115204_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113302","article-title":"Fibroblast activation protein drives tumor metastasis via a protease-independent role in invadopodia stabilization","volume":"42","author":"Bukhari","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.intimp.2025.115204_bb0240","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1593\/neo.121850","article-title":"Targeting inhibition of fibroblast activation protein-\u03b1 and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments","volume":"15","author":"Christiansen","year":"2013","journal-title":"Neoplasia"},{"issue":"18","key":"10.1016\/j.intimp.2025.115204_bb0245","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"issue":"695","key":"10.1016\/j.intimp.2025.115204_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9229","article-title":"A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","volume":"15","author":"Melero","year":"2023","journal-title":"Sci. Transl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:07:07Z","timestamp":1757912827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925011944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"alternative-id":["S1567576925011944"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115204","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115204"}}